

5.50.002

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	1 of 16

Last Review Date: March 6, 2026

Infliximab

Description

Remicade (infliximab), **Avsola** (infliximab-axxq), **Inflectra** (infliximab-dyyb), **Infliximab**, **Ixifi** (infliximab-qbtx), **Renflexis** (infliximab-abda)

Preferred products: Inflectra, Infliximab, Remicade

Background

Remicade (infliximab), Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), infliximab, Ixifi (infliximab-qbtx) and Renflexis (infliximab-abda) are tumor necrosis factor (TNF- α) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic processes, including the inflammation response associated with some autoimmune inflammatory diseases. Avsola, Ixifi, Inflectra and Renflexis are biosimilars to Remicade. Infliximab marketed by Janssen Biotech is an unbranded biologic of Remicade. Infliximab is identical in composition and produced from the same cell line and at the same manufacturing sites as Remicade. It is labeled for all currently approved Remicade indications and has the same safety and efficacy profile as Remicade (1-6).

Outpatient hospital infusion costs may be 2-3 times more compared to other sites of care suggesting an immediate opportunity exists for lowering spending on select infusion specialty medications. Services for patients requiring infused specialty medications may be provided through a physician's in-office infusion program or free-standing ambulatory infusion center. These options provide access to quality care at a lower cost that may be more convenient for the patient. In addition, patients that receive home infusion therapy have been shown to experience better outcomes, fewer complications for patients with certain conditions and,

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	2 of 16

improved quality of life and preference, including more personalized attention which helps avoid stress (7).

Regulatory Status

“Infliximab” will be used to refer to all infliximab products in this policy.

Infliximab is FDA-approved for the following indications: (1-6)

Crohn’s disease (CD):

- Indicated for reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.
- Indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease.

Ulcerative colitis (UC):

- Indicated for reducing signs and symptoms, inducing, and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

Rheumatoid arthritis (RA):

- Used in combination with methotrexate for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis.

Ankylosing spondylitis (AS):

- Indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

Psoriatic arthritis (PsA):

- Indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.

Plaque psoriasis (PsO):

- Indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	3 of 16

Pediatric ulcerative colitis:

- Indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

Infliximab Off-Label Uses: (8-19)

1. Axial spondyloarthritis
2. Behçet's syndrome
3. Granulomatosis with polyangiitis (Wegener's granulomatosis)
4. Hidradenitis Suppurativa (HS)
5. Juvenile idiopathic arthritis
6. Pyoderma gangrenosum
7. Sarcoidosis
8. Takayasu's arteritis
9. Uveitis

Infliximab carries a boxed warning regarding the increased risk of serious infections and malignancies. Patients treated with infliximab are at increased risk for developing serious infections that may lead to hospitalization or death. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including infliximab. Treatment with infliximab should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions and/or patients taking concomitant immunosuppressants such as corticosteroids or methotrexate may be at greater risk of infection (1-6).

Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients receiving infliximab. Prescribers should exercise caution in considering the use of infliximab in patients with these hematologic abnormalities and should consider discontinuation of infliximab if these disorders develop (1-6).

Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving infliximab, including patients who have previously received treatment for latent or active tuberculosis. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating infliximab and periodically during therapy (1-6).

Use of TNF blockers, including infliximab has been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. In some instances, HBV

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	4 of 16

reactivation occurring in conjunction with TNF blocker therapy has been fatal. Patients should be tested for HBV infection before initiating TNF blocker therapy, including infliximab (1-6).

Infliximab has been associated with adverse outcomes in patients with moderate to severe heart failure and should be used in patients with heart failure only after consideration of other treatment options (1-6).

It is recommended that live vaccines not be given concurrently. At least a six month waiting period following birth is recommended before the administration of live vaccines to infants born to female patients treated with infliximab (1-6).

It is recommended that all pediatric patients be brought up to date with all vaccinations prior to initiating infliximab. The interval between vaccination and initiation of infliximab therapy should be in accordance with current vaccination guidelines (1-6).

Related policies

Cimzia, Enbrel, Humira, Simponi, Zymfentra

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Infliximab may be considered **medically necessary** if the conditions indicated below are met.

Infliximab may be considered **investigational** for all other indications.

Prior-Approval Requirements

Diagnoses

Patient must have **ONE** of the following:

Age 6 years of age or older

1. Moderate to severely active Crohn's disease (CD)
 - a. Inadequate treatment response, intolerance, or contraindication to conventional therapy for CD (See Appendix 1)

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	5 of 16

- b. Up to date with all vaccinations prior to initiating therapy (pediatric patients)
- 2. Moderate to severely active ulcerative colitis (UC)
 - a. Inadequate treatment response, intolerance, or contraindication to conventional therapy for UC (See Appendix 1)
 - b. Up to date with all vaccinations prior to initiating therapy (pediatric patients)

Age 12 years of age or older

- 1. Juvenile idiopathic arthritis (JIA)
 - a. Inadequate treatment response, intolerance, or contraindication to at least a 3-month trial of a self-injectable TNF inhibitor indicated for JIA

Age 18 years of age and older

- 1. Moderate to severely active rheumatoid arthritis (RA)
 - a. Inadequate treatment response, intolerance, or contraindication to at least a 3-month trial of methotrexate despite adequate dosing (i.e., titrated to 20 mg/week)
 - b. Concurrent methotrexate or leflunomide therapy for patients who do not show intolerance to or for whom methotrexate or leflunomide is not contraindicated
- 2. Active ankylosing spondylitis (AS) / axial spondyloarthritis
 - a. Inadequate treatment response to at least **TWO** non-steroidal anti-inflammatory drugs (NSAIDs) over a 4-week period in total at maximum recommended or tolerated anti-inflammatory doses
- 3. Severe plaque psoriasis (PsO)
 - a. At least 5% of body surface area (BSA) is affected OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected
 - b. Inadequate treatment response, intolerance, or contraindication to either conventional systemic therapy (see Appendix 1) or phototherapy

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	6 of 16

- i. If the patient is intolerant or contraindicated to one therapy then the patient must have an inadequate response, intolerance, or contraindication to the other treatment option
4. Active psoriatic arthritis (PsA)
 - a. Inadequate treatment response, intolerance, or contraindication to a 3-month trial of at least **ONE** conventional DMARD (see Appendix 2)
5. Behçet's syndrome
6. Granulomatosis with polyangiitis (Wegener's granulomatosis)
7. Hidradenitis suppurativa (HS)
8. Pyoderma gangrenosum
9. Sarcoidosis
10. Takayasu's arteritis
11. Uveitis
 - a. Inadequate treatment response, intolerance, or contraindication to a trial of immunosuppressive therapy for uveitis

AND ALL of the following:

1. TB test confirming no active tuberculosis **OR** if latent tuberculosis infection is present, treatment for the infection to be started prior to use of infliximab products
2. **NO** active infections
3. **NOT** to be used in combination with any other biologic DMARD or targeted synthetic DMARD (See Appendix 2)
4. Patient is not at risk for HBV infection **OR** is at risk for HBV infection and HBV infection has been ruled out **OR** treatment for HBV infection has been initiated
5. **NOT** given concurrently with live vaccines
6. **Non-preferred medications only:** Inadequate treatment response, intolerance, or contraindication to **ONE** of the preferred products (Infliximab, Remicade)

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	7 of 16

Prior – Approval *Renewal* Requirements

Diagnoses

Patient must have **ONE** of the following:

Age 6 years of age or older

1. Crohn's disease (CD)
2. Ulcerative colitis (UC)

Age 12 years of age and older

1. Juvenile idiopathic arthritis (JIA)

Age 18 years of age or older

1. Rheumatoid arthritis (RA)
2. Ankylosing spondylitis (AS) / axial spondyloarthritis
3. Psoriatic arthritis (PsA)
4. Plaque psoriasis (PsO)
5. Behçet's syndrome
6. Granulomatosis with polyangiitis (Wegener's granulomatosis)
7. Hidradenitis suppurativa (HS)
8. Pyoderma gangrenosum
9. Sarcoidosis
10. Takayasu's arteritis
11. Uveitis

AND ALL of the following:

- a. Condition has improved or stabilized
- b. Absence of active infection (including tuberculosis and hepatitis B virus (HBV))
- c. **NOT** to be used in combination with any other biologic DMARD or targeted synthetic DMARD (See Appendix 2)
- d. **NOT** given concurrently with live vaccines

Section: Prescription Drugs	Effective Date: April 1, 2026
Subsection: Gastrointestinal Agents	Original Policy Date: May 20, 2011
Subject: Infliximab	Page: 8 of 16

Pre - PA Allowance

None

Prior - Approval Limits

Duration 4 months (4 cycles per 4 months) for all diagnoses except RA and JIA
 6 months (5 cycles per 6 months) for RA and JIA

Prior – Approval *Renewal* Limits

Duration 12 months (7 cycles per year) for all diagnoses except AS
 12 months (9 cycles per year) for AS

Please reference tables for specific dosing in vials for initiation and continuation criteria:

Indications	Initiation	Continuation
All Diagnoses <u>except</u> AS, RA & JIA Dosing: 5 mg/kg/cycle **Note: CD and UC dosing can go up to 10 mg/kg/cycle	4 cycles of treatment for 4 months	7 cycles of treatment for 1 year (every 8 weeks)
AS Dosing: 5 mg/kg/cycle	4 cycles of treatment for 4 months	9 cycles of treatment for 1 year (every 6 weeks)
RA & JIA Dosing: 3 mg/kg/cycle **Note: Non-responders can increase to every 4 weeks dosing OR 10 mg/kg/cycle	5 cycles of treatment for 6 months	7 cycles of treatment for 1 year (every 8 weeks)

Patient Weight		Indications		
		RA & JIA	All Diagnoses <u>except</u> RA & JIA	Non-responders RA, JIA, CD, UC
0 – 10 kg	up to 22 lbs	1 vial/cycle	1 vial/cycle	1 vial/cycle
11 – 20 kg	23 – 44 lbs	1 vial/cycle	1 vial/cycle	2 vials/cycle
21 – 30 kg	45 – 66 lbs	1 vial/cycle	2 vials/cycle	3 vials/cycle
31 – 40 kg	67 – 88 lbs	2 vials/cycle	2 vials/cycle	4 vials/cycle
41 – 50 kg	89 – 110 lbs	2 vials/cycle	3 vials/cycle	5 vials/cycle
51 – 60 kg	111 – 132 lbs	2 vials/cycle	3 vials/cycle	6 vials/cycle

5.50.002

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	9 of 16

61 – 65 kg	133 – 145 lbs	2 vials/cycle	4 vials/cycle	7 vials/cycle
66 – 70 kg	146 – 154 lbs	3 vials/cycle	4 vials/cycle	7 vials/cycle
71 – 72 kg	155 – 159 lbs	3 vials/cycle	4 vials/cycle	7 vials/cycle
73 – 80 kg	160 – 176 lbs	3 vials/cycle	4 vials/cycle	8 vials/cycle
81 – 90 kg	177 – 198 lbs	3 vials/cycle	5 vials/cycle	9 vials/cycle
91 – 100 kg	199 – 220 lbs	3 vials/cycle	5 vials/cycle	10 vials/cycle
101 – 110 kg	221 – 242 lbs	4 vials/cycle	6 vials/cycle	11 vials/cycle
111 – 120 kg	243 – 264 lbs	4 vials/cycle	6 vials/cycle	12 vials/cycle
121 – 122 kg	265 – 269 lbs	4 vials/cycle	6 vials/cycle	12 vials/cycle
123 – 130 kg	270 – 286 lbs	4 vials/cycle	7 vials/cycle	13 vials/cycle
131 – 132 kg	287 – 290 lbs	4 vials/cycle	7 vials/cycle	14 vials/cycle
133 – 140 kg	291 – 308 lbs	5 vials/cycle	7 vials/cycle	14 vials/cycle
141 – 150 kg	309 – 330 lbs	5 vials/cycle	8 vials/cycle	15 vials/cycle

Rationale

Summary

Infliximab is a tumor necrosis factor (TNF α) blocker. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic processes, including the inflammation response associated with some autoimmune inflammatory diseases. Infliximab carries a boxed warning regarding the increased risk of serious infections and malignancies. Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have also been reported in patients receiving infliximab. Cases of reactivation of hepatitis B virus (HBV) and tuberculosis or new tuberculosis infections have been observed in patients receiving infliximab. It is recommended that live vaccines not be given concurrently. It is recommended that all pediatric and adult patients be brought up to date with all vaccinations prior to initiating infliximab (1-6).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of infliximab while maintaining optimal therapeutic outcomes.

References

1. Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc.; February 2025.
2. Inflectra [package insert]. New York, NY: Pfizer Inc; September 2025.
3. Renflexis [package insert]. Jersey City, NJ: Organon LLC; October 2025.
4. Ixifi [package insert]. New York, NY: Pfizer Inc; October 2025.

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	10 of 16

5. Avsola [package insert]. Thousand Oaks, CA: Amgen Inc.; August 2025.
6. Infliximab [package insert]. Horsham, PA. Janssen Biotech, Inc. March 2025.
7. Polinski J, Kowal M, Gagnon M, et al. Home infusion: Safe, clinically effective, patient preferred, and cost saving. *Healthcare* 2016 04:004.
8. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum* 2007; 56:3096.
9. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. *Ann Rheum Dis* 2010; 69:718.
10. Lahdenne P, Vähäsalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. *Ann Rheum Dis* 2003; 62:245.
11. Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. *Ann Rheum Dis* 2011; 70:1605.
12. Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. *J Rheumatol.* 2013 Oct;40(10):1749-55.
13. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol.* 2011;65(1):137-174.
14. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies; 2015 update. *Ann Rheum Dis.* 2016;75(3):499-510.
15. Gladman DD, Antoni C, P Mease, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis* 2005;64(Suppl II):ii14–ii17.
16. Peluso R, Lervolino S, Vitiello M, et al. Extra-articular manifestations in psoriatic arthritis patients. *Clin Rheumatol.* 2014 May 8. [Epub ahead of print].
17. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis* 2011;70:896–904.
18. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res.* 2011;63(4):465-482.

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	11 of 16

19. Ringold S, Weiss PF, Beukelman T, et al. 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. *Arthritis & Rheumatism*. 2013;65:2499-2512.

Policy History

Date	Action
October 2011	Revised ulcerative colitis section to be approvable for ages 6 and above and revised methotrexate requirements to allow for approval if the member has either shown intolerance to methotrexate or for whom methotrexate is contraindicated
September 2012	Annual review and reference update
March 2013	Annual editorial review and reference update Addition to criteria to rule out or treat HBV infection prior to initiation of therapy; update of contraindicated concomitant therapy; added NO live vaccine within two weeks
September 2013	Annual editorial review
September 2014	Age limit lowered to 12 and older for diagnosis of RA and renewal limit to 18 months
June 2015	Annual review and reference update
September 2016	Annual editorial review and reference update. Addition of Inflectra and not given concurrently with live vaccines per SME Policy code changed from 5.09.02 to 5.50.02
December 2016	Change in approval lengths for initiation and continuation and quantity limits put in place based on diagnosis
March 2017	Annual review
July 2017	Annual review
August 2017	Addition of Renflexis and addition of new indications: axial spondyloarthritis, Behçet's syndrome, granulomatosis with polyangiitis (Wegener's granulomatosis), hidradenitis Suppurativa, pyoderma gangrenosum, sarcoidosis, Takayasu's arteritis, uveitis. Addition of tried and fail requirements to the indications per SGM criteria
September 2017	Annual review
December 2017	Annual editorial review Change of AS dosing from 8 cycles to 9 cycles Addition of dosing to off-label uses Addition of Appendix 1 & 2

5.50.002

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	12 of 16

January 2018	Addition of Ixifi
March 2018	Annual editorial review Defined JIA dosing
July 2018	Addition of additional requirements to initiation criteria For diagnosis of PsA: inadequate response, intolerance or contraindication to a 3-month trial of at least ONE conventional DMARD For diagnosis of PsO: Inadequate response, intolerance, or contraindication to either conventional systemic therapy (see Appendix 2) or phototherapy and if the patient is intolerant or contraindicated to either therapy then the other treatment option needs to be tried
August 2018	Updated dosing chart
September 2018	Annual editorial review and reference update
March 2019	Annual review
September 2019	Annual review
December 2019	Annual review. Removed initial requirement for patient to have fistulizing Crohn's Disease. Addition of biosimilar Avsola
March 2020	Annual review and reference update
June 2020	Annual review
September 2020	Annual review and reference update
December 2020	Annual editorial review and reference update. Added Avsola, Inflectra, and Renflexis as preferred products. Added requirement that Remicade has to t/f at least two of the preferred products
February 2021	Clarifying language added to pharmacy benefit
March 2021	Annual editorial review. Clarification added to the t/f, intolerance, C/I to preferred products requirement indicating that it only applies to claims adjudicated through the pharmacy benefit. Updated Appendix 2.
May 2021	Exception for JIA added under PA duration
June 2021	Annual review
January 2022	Addition of infliximab as a preferred product for claims adjudicated through the pharmacy benefit. Editorial update.
March 2022	Annual review and reference update
September 2022	Annual review
December 2022	Annual review
June 2023	Annual review
December 2023	Annual review. Per FEP, changed preferred products to Avsola, Infliximab, and Remicade. Also removed Medex requirement. Added t/f requirement of ONE preferred agent to initiation. Also per FEP, increased max dosage for UC to 10 mg/kg/cycle
March 2024	Annual review and reference update
June 2024	Annual review

5.50.002

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	13 of 16

September 2024 Annual editorial review and reference update. Per FEP, added Inflectra as a preferred product and removed Avsola as a preferred product for 2025

March 2025 Annual review and reference update

March 2026 Annual review and reference update

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	14 of 16

Appendix 1 - List of Conventional Therapies

Conventional Therapy Options for CD	
1. Mild to moderate disease – induction of remission:	<ul style="list-style-type: none"> a. Oral budesonide, oral mesalamine b. Alternatives: metronidazole, ciprofloxacin
2. Mild to moderate disease – maintenance of remission:	<ul style="list-style-type: none"> a. Azathioprine, mercaptopurine b. Alternatives: oral budesonide, methotrexate intramuscularly (IM)
3. Moderate to severe disease – induction of remission:	<ul style="list-style-type: none"> a. Prednisone, methylprednisolone intravenously (IV) b. Alternatives: methotrexate IM
4. Moderate to severe disease – maintenance of remission:	<ul style="list-style-type: none"> a. Azathioprine, mercaptopurine b. Alternative: methotrexate IM
5. Perianal and fistulizing disease – induction of remission	<ul style="list-style-type: none"> c. Metronidazole ± ciprofloxacin
6. Perianal and fistulizing disease – maintenance of remission	<ul style="list-style-type: none"> d. Azathioprine, mercaptopurine e. Alternative: methotrexate IM

Conventional Therapy Options for UC	
1. Mild to moderate disease – induction of remission:	<ul style="list-style-type: none"> a. Oral mesalamine (e.g., Asacol, Lialda, Pentasa), balsalazide, olsalazine b. Rectal mesalamine (e.g., Canasa, Rowasa) c. Rectal hydrocortisone (e.g., Colocort, Cortifoam) d. Alternatives: prednisone, azathioprine, mercaptopurine, sulfasalazine
2. Mild to moderate disease – maintenance of remission:	<ul style="list-style-type: none"> a. Oral mesalamine, balsalazide, olsalazine, rectal mesalamine b. Alternatives: azathioprine, mercaptopurine, sulfasalazine
3. Severe disease – induction of remission:	<ul style="list-style-type: none"> a. Prednisone, hydrocortisone IV, methylprednisolone IV b. Alternatives: cyclosporine IV, tacrolimus, sulfasalazine
4. Severe disease – maintenance of remission:	<ul style="list-style-type: none"> a. Azathioprine, mercaptopurine b. Alternative: sulfasalazine
5. Pouchitis:	<ul style="list-style-type: none"> a. Metronidazole, ciprofloxacin b. Alternative: rectal mesalamine

Section:	Prescription Drugs	Effective Date:	April 1, 2026
Subsection:	Gastrointestinal Agents	Original Policy Date:	May 20, 2011
Subject:	Infliximab	Page:	15 of 16

Appendix 2 – List of DMARDs

Conventional disease-modifying antirheumatic drugs (DMARDs)

Generic Name	Brand Name
azathioprine	Azasan, Imuran
cyclophosphamide	Cytosan
cyclosporine	Neoral, Gengraf, Sandimmune
hydroxychloroquine	Plaquenil
leflunomide	Arava
methotrexate	Rheumatrex, Trexall
mycophenolate	Cellcept
sulfasalazine	Azulfidine, Sulfazine

Biological disease-modifying antirheumatic drugs (DMARDs)

Generic Name	Brand Name
abatacept	Orencia
adalimumab	Humira
anakinra	Kineret
bimekizumab-bkzx	Bimzelx
brodalumab	Siliq
certolizumab	Cimzia
etanercept	Enbrel
golimumab	Simponi/Simponi Aria
guselkumab	Tremfya
infliximab	Remicade
infliximab-dyyb	Zymfentra
ixekizumab	Taltz
risankizumab-rzaa	Skyrizi
rituximab	Rituxan
sarilumab	Kevzara
secukinumab	Cosentyx
spesolimab-sbzo	Spevigo
tildrakizumab-asmn	Ilumya
tocilizumab	Actemra
ustekinumab	Stelara
vedolizumab	Entyvio

Targeted synthetic disease-modifying antirheumatic drugs (DMARDs)

Generic Name	Brand Name
apremilast	Otezla

5.50.002

Section: Prescription Drugs

Effective Date: April 1, 2026

Subsection: Gastrointestinal Agents

Original Policy Date: May 20, 2011

Subject: Infliximab

Page: 16 of 16

baricitinib	Olumiant
deucravacitinib	Sotyktu
tofacitinib	Xeljanz
upadactinib	Rinvog